Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has disclosed that it set July 29, 2025, as the record date to determine shareholders entitled to exercise voting rights at the upcoming Extraordinary General Meeting of Shareholders.
📊 [Key Disclosure Details & Financial Figures]
- Disclosure Title: Setting of Record Date or Period for Closure of Shareholder Register
- Record Date: July 29, 2025
- Closure Period for Shareholder Register: N/A (Closure period not set due to electronic registration of shares)
- Reason for Setting: Determination of shareholders entitled to vote at the Extraordinary General Meeting of Shareholders
- Other Important Details:
- Governing Laws and Articles: Article 354 of the Commercial Code and Article 14 of the Company’s Articles of Incorporation
- Pursuant to the Act on Electronic Registration of Stocks, Bonds, Etc., setting a closure period is unnecessary for electronically registered shares; thus, the suspension period for share transfer is omitted.
- Related Disclosure: May 22, 2025: Decision on Corporate Spin-off
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verifying Record Date (July 29, 2025) and Subsequent EGM Official Disclosures
This disclosure provides notice of setting the record date to determine eligible voting shareholders for the upcoming Extraordinary General Meeting of Shareholders related to the corporate spin-off.
Monitoring follow-up announcements regarding the EGM notice and relevant procedures after the record date (July 29, 2025) is essential.
Relevant details can be verified in subsequent official disclosures and periodic reports.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
